Last reviewed · How we verify
NCT03358836
Joint Health Study
trial in Hemophilia B in 8 participants. Completed in 17 August 2020.
17 August 2020
Quick facts
| Lead sponsor | Bloodworks |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 8 |
| Start date | 15 November 2017 |
| Primary completion | 17 August 2020 |
| Estimated completion | 17 August 2020 |
| Sites | 5 locations across United States |
Conditions studied
- Hemophilia B — all drugs for Hemophilia B →
Sponsor
Bloodworks — full company profile →
Who can join
16 and older, male only, with Hemophilia B. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a prospective, non-randomized, controlled study to examine whether or not having a higher trough during prophylactic treatment with clotting factor offers better joint protection than the standard trough of 1% Factor IX (FIX or Factor 9). This study will test the hypothesis that an extended half-life (EHL) FIX product with an intended trough of \>10% could offer better protection than previous treatment concentrates. This study also examines whether or not joint damage could be diagnosed earlier using ultrasound images.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Asymptomatic Joint Bleeding and Joint Health in Hemophilia: A Review of Variables, Methods, and Biomarkers.
Gooding R, Thachil J, Alamelu J, Motwani J, et al · · 2021 · cited 27× · PMID 33833602 · DOI 10.2147/jbm.s304597
Verify or expand the search:
- PubMed search for NCT03358836
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Hemophilia B
Currently open trials in the same condition.
- NCT07080905 — Phase 3, Open-label, Single-dose Study of CSL222 in Adolescent Male Subjects (≥ 12 to < 18 Years of Age) With Severe or · Phase 3 · recruiting
- NCT06727669 — Longitudinal Cohort of Thrombosis and Hemostasis Diseases · recruiting
- NCT06565481 — Measurement Properties in People with Hemophilia · NA · recruiting
- NCT06379789 — A Study to Investigate the Safety and Effectiveness of a Coagulation Factor IX Gene Insertion Therapy (REGV131-LNP1265) · Phase 1, PHASE2 · recruiting
- NCT06399289 — Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin (rIX-FP) in Chinese Subjects With Hemophilia B Pre · Phase 3 · active not recruiting
Other Bloodworks trials
Trials by the same sponsor.
- NCT07513532 — The Primary Purpose of This Study is to Determine if Biotin, Vitamin B7 is an Effective Way to Label Platelets in Surviv · Phase 1 · not yet recruiting
- NCT03787927 — Reversal of Dual Antiplatelet Therapy With Cold Stored Platelets · Phase 1, PHASE2 · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03358836 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Bloodworks
- Last refreshed: 22 June 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03358836.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing